What measures can companies take to ensure the safety of their employees amid the COVID-19 outbreak?

How fakers are taking advantage of the pandemic.

We asked medicine makers around the world to tell us how their professional and personal lives have changed during the ongoing COVID-19 crisis.

We must collaborate to address stability challenges in viral vector manufacturing.

How can pharma companies keep up with the rapidly changing Chinese regulatory landscape?

What’s the fastest route to a COVID-19 vaccine?

Claudia Zylberberg explains the importance of ancillary material quality for advancing cell and gene therapies.

Let’s reduce gene therapy manufacturing costs by optimizing cell lines, improving transfectants, and optimizing downstream purification.

Why are compounds still failing at the final hurdle?